Rallybio Presents P-I Single Ascending Dose Results of RLYB116 for Complement-Mediated Diseases at ICW 2023
Shots:
- The clinical data from the P-I first-in-human single ascending dose study evaluating RLYB116 (SC) in healthy patients, showed a reduction in free C5 ≤99% at 24hrs. for 100mg dose and at 12, 24, and 72hrs. for 300mg dose, well-tolerated with mild to mod. AEs and no drug-related serious AEs were seen
- Mean estimated elimination half-life for RLYB116 was >300hrs. The P-I multiple ascending dose study of RLYB116 is ongoing while the preliminary safety, PK & PD data are expected in Q4’23
- The company has 2 clinical-stage programs i.e., RLYB212, an anti-HPA-1a Ab for the prevention of fetal & neonatal alloimmune thrombocytopenia, and RLYB116, a C5 inhibitor indicated to treat several diseases of complement dysregulation, as well as additional programs in preclinical development
Ref: Businesswire | Image: AbCellera
Related News:- AbCellera Collaborated with Rallybio to Develop and Commercialize Novel Antibody-Based Therapies for the Treatment of Rare Diseases
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
